Investigational test may detect Alzheimer's disease at early stages

Published On 2022-07-30 04:30 GMT | Update On 2022-07-30 09:49 GMT

Currently, the only accurate diagnosis of Alzheimer's disease is through postmortem analyses after a patient dies, but investigators have now developed a highly sensitive method for quantifying levels of tau protein-a hallmark of the condition-in cerebrospinal fluid surrounding the brain and spinal cord.

The method, which relies on optical sensors and what's called "lab-on-fiber" technology, is described in a study published in Advanced Photonics Research and it can detect even slightly elevated levels of tau protein that may occur in the very early stages of Alzheimer's disease.

"Lab-on-fiber technology has been advancing in recent years, and its combination with nanometer-scale functional materials can be applied to small-volume samples for highly sensitive detection of molecules at low levels, thereby having potential for early screening and personalized medicine," said lead author Francesco Chiavaioli, PhD, MEng, of the National Research Council of Italy.

Reference:

Chiavaioli, F., Santano Rivero, D., Del Villar, I., Socorro-Leránoz, A.B., Zhang, X., Li, K., Santamaría, E., Fernández-Irigoyen, J., Baldini, F., van den Hove, D.L.A., Shi, L., Bi, W., Guo, T., Giannetti, A. and Matias, I.R. (2022), Ultrahigh Sensitive Detection of Tau Protein as Alzheimer's Biomarker via Microfluidics and Nanofunctionalized Optical Fiber Sensors. Adv. Photonics Res. 2200044. https://doi.org/10.1002/adpr.202200044

Article Source : Advanced Photonics Research

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Investigational test may detect Alzheimer's disease at early stages

Similar News

Patients with Allergies Face Elevated Risk of Developing Optic Neuritis: Study Shows

MS does not worsen menopause symptoms: study

Pre-existing mental health conditions increase the risk of Vascular dementia post COVID-19 infection: Study

High-Resolution 7-Tesla MRI Reveals Brain Microvessel Pulsations Linked to Aging: Study

Bristol Myers Squibb BMS 986446 gets USFDA fast track designation for Alzheimer's Disease

Telestroke patients more likely to receive treatment, but with greater delays: JAMA

Sarcoidosis Patients at Higher Risk of Psychiatric Symptoms, Meta-Analysis Finds

Poor sleep may accelerate brain ageing, reveals research